Manfredi R, Baltieri S, Tognolini A, Graziani R, Smaniotto D, Cellini N, Bonomo L
Department of Radiology, University of Verona, P.le L.A. Scuro 10, 37134, Verona, Italy,
Radiol Med. 2008 Dec;113(8):1143-56. doi: 10.1007/s11547-008-0312-3. Epub 2008 Sep 8.
Our primary objective was to describe the magnetic resonance (MR) imaging patterns of recurrent uterine cancer after surgery and their changes following concurrent chemoradiation. The secondary objective was to identify MR imaging predictors of outcome.
Twenty-two consecutive women with biopsy-proven recurrent uterine cancer after surgery (cervix 13 patients, endometrium nine patients) were enrolled in this prospective study. Inclusion criteria were MR imaging at diagnosis and during follow-up and eligibility for concurrent chemoradiation. MR images were assessed for signal intensity of the pelvic relapse on T2-weighted images, site of relapse and infiltration of adjacent organs. Pre- and posttreatment MR images were compared on the basis of the same criteria. The 3D volume of relapses after treatment was calculated, and tumour response to treatment was evaluated as complete, partial, no change or disease progression.
Recurrences appeared hyperintense on T2-weighted images in 22/22 (100%) patients. Pelvic relapse site was vagina in 5/22 (23%), vaginal vault in 9/22 (41%), vaginal vault with extension to the pelvic wall in 5/22 (23%) and pelvic wall in 3/22 (13%). Infiltration of adjacent organs was detected in 9/22 (41%) patients. The mean volume of recurrences on pretreatment MR images was 38.83 cm(3). On posttreatment MR images, relapses appeared hypointense in 19/22 (86%) patients and hyperintense in 3/22 (14%). The mean volume of recurrences on posttreatment MR images was 18.01 cm(3). Complete response was seen in 11/22 (50%) patients, partial response in 8/22 (36%) and no change in 3/22 (14%).
MR imaging can provide an evaluation of all parameters necessary for planning treatment and assessing response to treatment.
我们的主要目的是描述子宫癌术后复发的磁共振(MR)成像模式及其同步放化疗后的变化。次要目的是确定MR成像的预后预测因素。
本前瞻性研究纳入了22例经活检证实为子宫癌术后复发的连续女性患者(13例宫颈癌患者,9例子宫内膜癌患者)。纳入标准为诊断时及随访期间的MR成像以及符合同步放化疗条件。评估MR图像上盆腔复发灶在T2加权图像上的信号强度、复发部位及邻近器官的浸润情况。根据相同标准比较治疗前后的MR图像。计算治疗后复发灶的三维体积,并将肿瘤对治疗的反应评估为完全缓解、部分缓解、无变化或疾病进展。
22例患者(100%)的复发灶在T2加权图像上呈高信号。盆腔复发部位为阴道的有5/22(23%),阴道穹隆的有9/22(41%),阴道穹隆延伸至盆腔壁的有5/22(23%),盆腔壁的有3/22(13%)。9/22(41%)的患者检测到邻近器官浸润。治疗前MR图像上复发灶的平均体积为38.83 cm³。治疗后MR图像上,19/22(86%)的患者复发灶呈低信号,3/22(14%)呈高信号。治疗后MR图像上复发灶的平均体积为18.01 cm³。11/22(50%)的患者出现完全缓解,8/22(36%)为部分缓解,3/22(14%)无变化。
MR成像可对治疗计划制定及治疗反应评估所需的所有参数进行评估。